Tandem Diabetes Care (TNDM) Net Cash Flow Growth (5y) (2018 - 2026)
Tandem Diabetes Care (TNDM) Net Cash Flow Growth (5y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.73 Bn | 176.43 Bn | 6.27 Bn |
| 2 | Stryker | 128.82 Bn | 125.94 Bn | 3.81 Bn |
| 3 | Medtronic | 108.74 Bn | 99.52 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.40 Bn | 66.95 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 47.42 Bn | 43.74 Bn | 1.29 Bn |
| 6 | GE HealthCare Technologies | 28.47 Bn | 26.18 Bn | 1.98 Bn |
| 7 | Dexcom | 28.42 Bn | 27.30 Bn | 750.30 Mn |
| 8 | Smith & Nephew | 26.97 Bn | 26.40 Bn | - |
| 9 | Koninklijke Philips | 25.52 Bn | 22.39 Bn | 2.07 Bn |
| 10 | Tandem Diabetes Care | 1.15 Bn | 577.45 Mn | 136.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27.96% |
| Dec 31, 2025 | 40.69% |
| Sep 30, 2025 | 18.04% |
| Jun 30, 2025 | -42.96% |
| Mar 31, 2025 | -20.87% |
| Dec 31, 2024 | 29.45% |
| Sep 30, 2024 | -21.40% |
| Jun 30, 2024 | -38.73% |
| Mar 31, 2024 | 18.99% |
| Dec 31, 2023 | -33.43% |
| Sep 30, 2023 | -12.29% |
| Jun 30, 2023 | 17.88% |
| Mar 31, 2023 | -23.94% |
| Dec 31, 2022 | 96.67% |
| Sep 30, 2022 | 20.96% |
| Jun 30, 2022 | 29.49% |
| Mar 31, 2022 | 43.82% |
| Dec 31, 2021 | -28.81% |
| Sep 30, 2021 | 25.57% |
| Jun 30, 2021 | -16.51% |